Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Scabies · Bioequivalence trial in healthy volunteers

Alphapharm

Alphapharm Pty Ltd

Alphapharm trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, AU HQ
1982 Founded
187 Employees
TGA registrant Type
Company details
Status
Public
HQ
Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, AU
Founded
1982
Employees
187
Programs
30
Drugs
235
Patents
12
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

Alphapharm clinical trials

Registry index of 30 ClinicalTrials.gov studies linked to Alphapharm programs — each row shows trial ID, program name, phase, status, and indication.

Alphapharm trial registry — 30 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Alphapharm.

  1. Debio0123-101 — Phase 1

    Clinical update

  2. CLP24001 — Phase 1

    Clinical update

  3. CLP22001 — Phase 1

    Clinical update

  4. PTT101 — Phase 2

    Clinical update

  5. Debio 0123-106 — Phase 1

    Clinical update

  6. Debio 0123-102 — Phase 1

    Clinical update

  7. 23-01/ClindaTret-G — Phase 3

    Clinical update

  8. 21-01/ClotriBet-S — Phase 3

    Clinical update

Trial registry

30 studies
  5. 2023-504824-24-00

    Debio 0123-102

    Phase 1 active other

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    CTIS ↗
  24. 2024-515446-16-00

    CR6086-1-04

    Phase 2 active small_molecule

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.